Resources: Page 68

CT tracks patient response to CAR T-cell therapy
By Kate Madden Yee
Sunday, November 27 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-3 | Room E352In this session, German researchers will discuss how CT can help clinicians track patient response to chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma.
November 22, 2022
AI algorithm identifies multiple myeloma lesions on whole-body CT
By Erik L. Ridley
Sunday, November 27 | 9:00 a.m.-10:00 a.m. | S1-SSMK01-2 | Room E451BResearchers from the Mayo Clinic in Rochester, MN, will share how their deep-learning algorithm can detect multiple myeloma lesions on whole-body CT exams.
November 22, 2022
CT shows lingering COVID-19 effects more than a year after infection
By Kate Madden Yee
Sunday, November 27 | 9:00 a.m.-10:00 a.m. | S1-SSCH01-5 | Room E351The effects of COVID-19 on patients' lungs are evident on CT, even a year after initial infection, according to this Sunday morning presentation.
November 22, 2022
United Imaging to highlight work-in-progress platforms at RSNA
By AuntMinnie.com staff writers
United Imaging plans to highlight three work-in-progress CT and PET/CT systems at the upcoming RSNA meeting.
November 21, 2022
2020 02 05 17 09 8620 United Imaging Rsna 2019 400
AI, photon-counting CT will figure prominently at RSNA 2022
RSNA 2022 is just days away. What can attendees expect from this year's meeting? AuntMinnie.com's Director of Content and Strategy Stephen Wellman offers a preview.
November 21, 2022
2022 11 22 17 09 6446 2022 11 22 Rsna Wellman Stephen 400
Winter is a SPECT time of year: Imaging frostbite
By Will Morton
On Demand | NMMIEE-4 | Learning Center -- NMMIIn this course, nuclear medicine physician Dr. Erica Martin-Macintosh of Sanford Health in Fargo, ND, will discuss triaging frostbite injuries with multiphase technetium-99m methylenediphosphonate bone scintigraphy.
November 21, 2022
Recognizing PET emergent findings among various radiotracers
By Will Morton
On Demand | NMMIEE-9 | Learning Center -- NMMIIn this exhibit, Mayo Clinic researchers in Rochester have prepared a presentation on methods to detect the most common emergent diagnostic challenges radiologists will face on PET, with a focus on newer radiotracers.
November 21, 2022
AI model predicts early Alzheimer's disease
By Will Morton
Thursday, December 1 | 9:30 a.m.-10:30 a.m. | R3-SSNR15-1 | Room N226In this neuroradiology session, researchers will present details on an amyloid PET-based deep-learning algorithm for predicting Alzheimer's disease dementia that is generalizable across different amyloid PET radiotracers.
November 21, 2022
Ga-68 DOTATATE PET/CT predicts outcomes in Lutathera patients
By Will Morton
Thursday, December 1 | 9:30 a.m.-10:30 a.m. | R3-SSNMMI07-2 | Room S501Patients with neuroendocrine tumors (NETs) who are at high risk for poor outcomes following peptide receptor radionuclide therapy (PRRT) can be identified with semi-automated quantitative analysis of gallium-68 (GA-68) DOTATATE PET/CT scans, according to research to be presented in this session.
November 21, 2022
Which radiotracer is best for preoperative lymph node assessment?
By Will Morton
Wednesday, November 30 | 3:00 p.m.-4:00 p.m. | W7-SSBR09-2 | Room E451BIn this scientific talk, researchers will compare the performance of F-18 FDG and F-18 fluoroethylcholine in preoperative lymph node assessment of breast cancer patients on PET/MRI.
November 21, 2022
Nomograms help predict positive Pylarify scans in prostate cancer patients
By Will Morton
Wednesday, November 30 | 12:15 p.m.-12:45 p.m. | W5A-STCE-2 | Learning Center TheaterNomograms may help guide the selection of the most suitable prostate cancer patients for F-18 DCFPyL-PET/CT (Pylarify) imaging, according to research presented in this session.
November 21, 2022
Pylarify improves management of patients considered for FT
By Will Morton
Wednesday, November 30 | 9:30 a.m.-10:30 a.m. | W3-SSNMMI06-1 | Room S502The role of F-18 DCFPyL (Pylarify) PET/MRI in the management of men considered for focal ablative therapies (FT) will be discussed in this session, with results suggesting the approach may exclude nearly 30% of patients from focal therapy.
November 21, 2022
Previous Page
Page 68 of 725
Next Page